Cingulate Inc.
CING- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001862150
No open-market purchases or sales by Cingulate Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $9.88M in total; no superinvestor holds it.
Other share classesCINGW
Q3 2023 vs. Q2 2023
How the institutions holding Cingulate Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 14 | 20 | +6 |
| Shares | 429.6K | 1.36M | +932.9K (+217.2%) |
| Value | $400.3K | $964.5K | +$564.2K (+140.9%) |
New holders (6)
Institutions that held Cingulate Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 754,792 | $535.1K | 0.02% |
| Commonwealth Equity Services, LLC | 100,771 | $71.0K | 0.00% |
| MML Investors Services, LLC | 50,000 | $35.0K | 0.00% |
| Avantax Advisory Services, Inc. | 28,408 | $20.1K | 0.00% |
| UBS Group AG | 140 | $99 | 0.00% |
| JPMorgan Chase & Co | 22 | $16 | 0.00% |
Sold out (0)
Institutions that held Cingulate Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
None.